Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
75.1 kDa. DTT-reduced protein migrates as 20 kDa and 62 kDa due to glycosylation and proteolytic digestion
HEK 293 Cells
Greater than 97% by SDS-PAGE
Measured by its ability to bind with human LDLR in a functional ELISA Immobilized recombinant human PCSK9 at 10 µg/ml (100 µl/well) can bind biotinylated human LDLR. The ED50 for this effect is typically 15 ng/ml.
Less than 1.0 EU/µg protein (determined by LAL method).
Lyophilized from PBS, pH 7.4, 5-8% mannitol or trehalose
Centrifuge the vial before opening. Reconstitute in sterile PBS, pH 7.4 to 100 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, store at -20°C.
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway.